Stay updated on Pyrotinib+Capecitabine in Trastuzumab-Resistant Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the Pyrotinib+Capecitabine in Trastuzumab-Resistant Breast Cancer Clinical Trial page.

Latest updates to the Pyrotinib+Capecitabine in Trastuzumab-Resistant Breast Cancer Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedA new revision entry v3.4.3 was added to the history, and the prior revision v3.4.2 was removed.SummaryDifference0.1%

- Check15 days agoNo Change Detected
- Check30 days agoChange DetectedA new revision entry v3.4.2 was added to the history.SummaryDifference0.1%

- Check37 days agoChange DetectedThe study record history shows a new revision (v3.4.1) added and the previous revision (v3.4.0) removed.SummaryDifference0.1%

- Check51 days agoChange DetectedUI updates include a glossary toggle, a color-coded legend for additions and deletions (green/red), and new revision notes (v3.4.0), with minor wording changes such as 'No FEAR Act Data'.SummaryDifference1%

- Check58 days agoChange DetectedA new record version (v3.3.4) has been added to the Record History, reflecting updates to recruitment status, study status, and study design.SummaryDifference0.1%

- Check87 days agoChange DetectedA new revision entry 'Revision: v3.3.3' was added to the record history; the 'HHS Vulnerability Disclosure' link and the older 'Revision: v3.3.2' entry were removed from the page.SummaryDifference0.2%

Stay in the know with updates to Pyrotinib+Capecitabine in Trastuzumab-Resistant Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pyrotinib+Capecitabine in Trastuzumab-Resistant Breast Cancer Clinical Trial page.